Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort. Read more about Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.
Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis. Read more about Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.
Distinct pain profiles in patients with chronic obstructive pulmonary disease. Read more about Distinct pain profiles in patients with chronic obstructive pulmonary disease.
Distinct symptom experiences in subgroups of patients with COPD. Read more about Distinct symptom experiences in subgroups of patients with COPD.
Mannose-binding lectin deficiency and acute exacerbations of chronic obstructive pulmonary disease. Read more about Mannose-binding lectin deficiency and acute exacerbations of chronic obstructive pulmonary disease.
Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis. Read more about Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.
Differences in subjective and objective respiratory parameters in patients with chronic obstructive pulmonary disease with and without pain. Read more about Differences in subjective and objective respiratory parameters in patients with chronic obstructive pulmonary disease with and without pain.
Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis. Read more about Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.
COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. Read more about COPD and cognitive impairment: the role of hypoxemia and oxygen therapy.
The impact of SHS exposure on health status and exacerbations among patients with COPD. Read more about The impact of SHS exposure on health status and exacerbations among patients with COPD.
